Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL281853 | 0.84 | MAOB (0.57) | HTR2BTMEM97SIGMAR1S1PR5MAOB | |
| SCHEMBL17602160 | 0.79 | KDM4C (0.46) | HTR2BTMEM97SIGMAR1S1PR5MAOB | |
| SCHEMBL17602159 | 0.77 | MAPT (0.53) | HTR2BTMEM97SIGMAR1S1PR5MAOB | |
| SCHEMBL11838902 | 0.75 | MAOB (0.61) | MAOBMAOAALOX5GAAMAPT | |
| SCHEMBL17602191 | 0.69 | ALOX5 (0.51) | MAOBMAOAALOX5GAAMAPT | |
| SCHEMBL23882929 | 0.68 | MAOB (0.63) | HTR2BTMEM97SIGMAR1MAOBMAOA | |
| SCHEMBL30251066 | 0.68 | MAOB (0.63) | HTR2BTMEM97SIGMAR1MAOBMAOA | |
| SCHEMBL8557387 | 0.68 | RXRA (0.49) | — | |
| SCHEMBL8322978 | 0.68 | MAOB (0.49) | MAOBMAOAALOX5GAAMAPT | |
| SCHEMBL9878279 | 0.68 | MAOB (0.61) | MAOBMAOAALOX5GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066355-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12172998-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11535616-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2022-12-27 | — | — | US | disclosed |
| EP-3453710-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-3430008-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3193601-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10815234-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20180297999-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-10030017-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| WO-2017161012-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3193601-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9643965-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016044429-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194323-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | HTR2B 3026/4885TMEM97 4287/4885SIGMAR1 4186/4885 |
| US-12172998-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | HTR2B 3058/4885TMEM97 4222/4885SIGMAR1 4158/4885 |
| US-10030017-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | HTR2B 3026/4885TMEM97 4287/4885SIGMAR1 4186/4885 |
| US-20160083379-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | HTR2B 3058/4885TMEM97 4222/4885SIGMAR1 4158/4885 |
| US-11535616-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | HTR2B 3058/4885TMEM97 4222/4885SIGMAR1 4158/4885 |
| US-20170240546-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | HTR2B 3058/4885TMEM97 4222/4885SIGMAR1 4158/4885 |
| US-20200199122-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | HTR2B 3058/4885TMEM97 4222/4885SIGMAR1 4158/4885 |
| US-20180162857-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | HTR2B 3026/4885TMEM97 4287/4885SIGMAR1 4186/4885 |
| US-20230117519-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | HTR2B 3058/4885TMEM97 4222/4885SIGMAR1 4158/4885 |
| US-20180297999-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5C, KDM1A | HTR2B 3026/4885TMEM97 4287/4885SIGMAR1 4186/4885 |
| US-20210009585-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | HTR2B 3058/4885TMEM97 4222/4885SIGMAR1 4158/4885 |
| US-20250066355-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | HTR2B 3058/4885TMEM97 4222/4885SIGMAR1 4158/4885 |
| US-10815234-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5C | HTR2B 3058/4885TMEM97 4222/4885SIGMAR1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.